<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353665</url>
  </required_header>
  <id_info>
    <org_study_id>002-04</org_study_id>
    <nct_id>NCT00353665</nct_id>
  </id_info>
  <brief_title>Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)</brief_title>
  <official_title>Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lisbon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lisbon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate
      affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the
      calcium influx into the neurons), a drug used to treat AlzheimerÂ´s disease, on the
      progression of Amyotrophic Lateral Sclerosis (ALS). Memantine is added to riluzole (the
      single drug approved to treat ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2/3 trial in ALS patients Double-blinded, parallel, randomized (2 blocs, bulbar/spinal
      onset)

      Memantine + riluzole x Placebo + Memantine

      Inclusion criteria:

        -  &lt; 75 years at disease onset

        -  &lt; 3 years of disease progression

        -  ALS-FRS &gt; 24

        -  FVC &gt; 60

        -  Probable or definite disease (revised El Escorial criteria)

        -  No other medical condition

        -  Normal blood tests

        -  Regular medication on riluzole &gt; 1 month

        -  Nerve conduction studies ruling out conduction block

        -  EMG with widespread loss of motor units (revised El Escorial criteria)

        -  At least one hand with ADM strength &gt; 2 on MRC scale

      Duration - 2 years

      Evaluation - every 3 months

      Primary outcome - ALS-FRS Secondary -SF36, Hamilton depression scale, motor unit number
      estimation, neurophysiological index, strength (clinical evaluation); side-effects

      Intention to treat analysis

      60 patients

      number estimated for 50% change in decline rate of ALS-FRS
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALS-FRS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL, depression scale, strength (clinical evaluation), forced vital capacity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurophysiology (motor unit counting, neurophysiological index)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1 - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>memantine + riluzole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>riluzole + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine (Ebixa)</intervention_name>
    <description>10 mg bid</description>
    <arm_group_label>1 - active</arm_group_label>
    <other_name>Ebixa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riluzole</intervention_name>
    <description>riluzole 50 mg bid</description>
    <arm_group_label>1 - active</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definite or probable disease - revise El Escorial criteria

          -  Normal blood tests

          -  Riluzole treatment during 1 month or more

          -  EMG in accordance with El Escorial criteria

        Exclusion Criteria:

          -  Other diseases (such as PNP)

          -  Both ADM muscles &lt; 3 on MRC scale

          -  Conduction block on nerve conduction tests

          -  Disease duration &gt; 3 years

          -  ALS-FRS &lt; 25

          -  Forced vital capacity - &lt;60%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mamede de Carvalho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology- Hospital de Santa Maria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2006</study_first_posted>
  <last_update_submitted>March 30, 2009</last_update_submitted>
  <last_update_submitted_qc>March 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mamede de Carvalho</name_title>
    <organization>Instituto de Medicina Molecular</organization>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>memantine</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

